FagronLab | 2019 Towards the importance of a Roller Mill in compounding practice: An experimental approach Polonini HC, Loures da Silva S, Batista PF, Brandao MAF, Ferreira AO International Journal of Pharmaceutical Compounding, 23(2), 154-156 In this paper, the use of an ointment mill in final steps of compounding semisolid dosage forms is evaluated, showing better homogeneity when assessing content uniformity of progesterone 5%, estradiol 0.1%, and estriol 0.4% creams. Finally, the proposed cleaning procedure decreased the presence of compounded preparation to a “none-detection” level. Read more
Pentravan | 2019 Ex Vivo evaluation of intravaginal Progesterone and Testosterone to treat the luteal-phase deficiency and vaginal atrophy Laque LC, Raposo NRB, Brandao MAF, Ferreira AO, Polonini HC International Journal of Pharmaceutical Compounding, 23 (1), 77-81 The purpose of this study was to evaluate the transmucosal permeation of progesterone and testosterone using Pentravan as its vehicle for vaginal delivery. The permeation studies revealed that testosterone formulated with Pentravan is potentially effective in reaching the bloodstream and acts locally, whereas progesterone was mostly retained in the mucosa. Read more SEE PRODUCT
Pentravan | 2019 Topical Monomethylsilanetriol can deliver silicon to the viable skin Polonini HC, Ferreira AO, Brandao MAF, Raposo NRB International Journal of Cosmetic Science, 41(4), 405-409 The main objective of the study was to assess whether SiliciuMax (liquid) can deliver silicon to the epidermis and dermis, when applied topically in a cream. Evidence shows that SiliciuMax applied topically can deliver silicon to the skin in biorelevant levels for cosmetic purposes. Read more SEE PRODUCT
Pentravan | 2019 Transdermal delivery of Metformin Hydrochloride from a semisolid vehicle Polonini HC, Lopes CPJ, Andrade Junquiera L, Loures S, Raposo NRB, Brandao MAF, Ferreira AO International Journal of Pharmaceutical Compounding, 23(1), 65-69 The use of Pentravan to deliver metformin hydrochloride through the skin was evaluated. A 46.7% permeation percentage was found, with a drug flux of 3.91 µg cm/-2/h-1 and a lag time of 0.51 h, suggesting the transdermal route can be an option for patients searching for diverse clinical effects. Read more SEE PRODUCT
Pentravan | 2019 Transdermal Desmopressin as an alternative dosage form for the treatment of nocturia Junqueira LA, Bezerra AA jr, Lopes Candido PJ, Polonini HC, Ferreira AO, Raposo NRB, Brandao MAF Journal of Multidisciplinary Engineering Science and Technology, 6 (10), 888-892 The main objective of the study was to evaluate the ex vivo permeation of a transdermal formulation containing desmopressin, using Pentravan®. The formulation developed was able to promote transdermal absorption of desmopressin, showing a permeation percentage of 21.5%. Thus, sufficient amounts of desmopressin were delivered to achieve a systemic effect. Read more SEE PRODUCT
Pentravan | 2019 Activators of SIRT1 in wound repair: An animal model study Christovam AC, Theodoro V, Sampaio Mendoça FA, Marretto Esquisatto MA, Tech dos Santos GM, Corezola do Amaral ME Archives of Dermatological Research, 311(3), 193-201 The study aimed to study the effect of caloric restriction (CR) and resveratrol (Rv) in wound repair. Results show that the CR and Rv group had enhanced numbers of blood vessels, VEGF, fibroblast, birefringent collagen fiber areas in the lesion and may modulate angiogenesis, fibroplasia, and collagenesis. Read more SEE PRODUCT
Pentravan | 2019 Permeation efficacy of a transdermal vehicle with steroidal hormones and nonsteroidal anti-inflammatory agents as model drugs Junqueira LA, Polonini HC, Loures S, Raposo NRB, Ferreira AO, Brandao MAF Current Drug Delivery, 16(2), 136-141 In this study, a new transdermal vehicle was evaluated using progesterone, estradiol, estradiol + estriol (Biest) and ketoprofen administered as model drugs. For all drugs, sufficient amounts were delivered to achieve a systemic effect, and it was also possible to decrease the amount of emulsion applied. Read more SEE PRODUCT
TrichoConcept | 2019 Effects of Trichosol™ on increasing the anagen phase of the capillary cycle of volunteers Velasco PA, Oliveira A, Amaral F, Rocha Oliveira C Journal of Cosmetology and Trichology, 5(1), 139 This study aimed to investigate the potential of Trichosol™, associated with Minoxidil (3%), in the promotion of hair growth. The results indicated that after treatment for 90 days with the combination of Minoxidil (3%) and Trichosol™, both sexes presented increase in the percentage of anagen phase. Read more SEE PRODUCT
Pentravan | 2019 The complexation of steroid hormones into cyclodextrin alters the toxic effects on the biological parameters of Zebrafish (Danio rerio) Galvao da Silva MC, Freitas da Silva J, Pinheiro Santos T, Correia da Silva NP, Rodrigues dos Santos A, Correa de Andrade AL, Lima da Silva Souza EH, Ribeiro Sales Cadena M, Bezerra de Sa F, Amaro da Silva V jr, Gonçalves Cadena P Chemosphere, 214, 330-340 This study aimed to evaluate the toxicity of progesterone (P4F) and estradiol (E2F) and their effect complexed into cyclodextrins, and evaluate them as endocrine disruptors through biological parameters of Danio rerio. According to these results, there is a higher toxicity effect of hormones in the free form. Read more SEE PRODUCT
Pentravan | 2018 Feasibility study evaluating Pentravan® for the intravaginal administration of active pharmaceutical ingredients to reduce pelvic pain related to endometriosis Polonini HC, Loures S, Alves MC, Ferreira AO, Brandao MAF, Raposo NRB Drug Delivery Letters, 8(3), 200-208 This study aimed to evaluate the preliminary feasibility of using Pentravan® to compound dienogest, gestrinone, nimesulide and piroxicam and their vaginal administration to patients with pelvic pain associated with endometriosis (PPRE). Pentravan® seems to be a feasible intravaginal vehicle, particularly for delivery of dienogest and gestrinone for for PPRE treatment. Read more SEE PRODUCT